Oluic Branisav, Paunovic Ivan, Loncar Zlatibor, Djukic Vladimir, Diklic Aleksandar, Jovanovic Milan, Garabinovic Zeljko, Slijepcevic Nikola, Rovcanin Branislav, Micic Dusan, Filipovic Aleksandar, Zivaljevic Vladan
Emergency Center, Clinical Center of Serbia, Pasterova 2, Belgrade, 11000, Serbia.
Center for Endocrine Surgery, Clinical Center of Serbia, Pasterova 2, Belgrade, 11000, Serbia.
BMC Cancer. 2017 May 25;17(1):371. doi: 10.1186/s12885-017-3370-x.
Hurthle cell carcinoma makes up 3 to 5% of all thyroid cancers and is considered to be a true rarity. The aim of our study was to analyze clinical characteristics and survival rates of patients with Hurthle cell carcinoma.
Clinical data regarding basic demographic characteristics, tumor grade, type of surgical treatment and vital status were collected. Methods of descriptive statistics and Kaplan-Meier survival curves were used for statistical analysis. Cox proportional hazards regression was used to identify independent predictors.
During the period from 1995 to 2014, 239 patients with Hurthle cell carcinoma were treated at our Institution. The average age of the patients was 54.3, with female to male ratio of 3.6:1 and average tumor size was 41.8 mm. The overall recurrence rate was 12.1%, with average time for relapse of 90.74 months and average time without any signs of the disease of 222.4 months. Overall 5-year, 10-year and 20-year survival rates were 89.4%, 77.2%, 61.9% respectively. The 5-year, 10-year and 20-year cancer specific survival rates were 94.6%, 92.5%, 87.4%, respectively. When disease free interval was observed, 5-year, 10-year and 20-year rates were 91.1%, 86.2%, 68.5%, respectively. The affection of both thyroid lobes and the need for reoperation due to local relapse were unfavorable independent prognostic factors, while total thyroidectomy as primary procedure was favorable predictive factor for cancer specific survival.
Hurthle cell carcinoma is a rare tumor with an encouraging prognosis and after adequate surgical treatment recurrences are rare.
嗜酸性细胞癌占所有甲状腺癌的3%至5%，被认为是一种真正罕见的疾病。我们研究的目的是分析嗜酸性细胞癌患者的临床特征和生存率。
收集有关基本人口统计学特征、肿瘤分级、手术治疗类型和生命状态的临床数据。采用描述性统计方法和Kaplan-Meier生存曲线进行统计分析。使用Cox比例风险回归来确定独立预测因素。
1995年至2014年期间，我们机构共治疗了239例嗜酸性细胞癌患者。患者的平均年龄为54.3岁，女性与男性的比例为3.6:1，平均肿瘤大小为41.8毫米。总复发率为12.1%，平均复发时间为90.74个月，无疾病迹象的平均时间为222.4个月。总体5年、10年和20年生存率分别为89.4%、77.2%、61.9%。5年、10年和20年癌症特异性生存率分别为94.6%、92.5%、87.4%。观察无病间期时，5年、10年和20年率分别为91.1%、86.2%、68.5%。双侧甲状腺受累以及因局部复发需要再次手术是不利的独立预后因素，而全甲状腺切除术作为主要手术是癌症特异性生存的有利预测因素。
嗜酸性细胞癌是一种罕见肿瘤，预后令人鼓舞，经过充分的手术治疗后复发罕见。
